Transjugular intrahepatic portosystemic shunt: current indications, patient selection and results.

BACKGROUND Inserting a transjugular intrahepatic portosystemic shunt by means of interventional radiology has become the procedure of choice for decompression of portal hypertension. The indications and criteria for patient selection have been expanded and refined accordingly. OBJECTIVES To review our experience with TIPS and analyze the results with emphasis on patient selection and indication (conventional vs. atypical). METHODS In this retrospective analysis in a single center all cases were managed by a multidisciplinary team (comprising liver surgery and transplantation, hepatology, imaging, interventional radiology and intensive care). RESULTS Between August 2003 and December 2009, 34 patients (mean age 51, range 27-76 years) were treated with TIPS. The cause of portal hypertension was cirrhosis (23 cases), hypercoagulability complicated by Budd-Chiari syndrome (n=6), and acute portal vein thrombosis (n=5). Clinical indications for TIPS included treatment or secondary prevention of variceal bleeding (10 cases), refractory ascites (n=18), mesenteric ischemia due to acute portal vein thrombosis (n=5), and acute liver failure (n=1). TIPS was urgent in 18 cases (53%) and elective in 16. Three deaths occurred following urgent TIPS. The overall related complication rate was 32%: trasient encephalopathy (6 cases), ischemic hepatitis (n=2), acute renal failure (n=2) and bleeding (n=1). Long-term results of TIPS were defined as good in 25 cases (73%), fair in 4 (12%) and failure in 5 (15%). In three of five patients with mesenteric ischemia following acute portal vein thrombosis, surgery was obviated. Revision of TIPS due to stenosis or thrombosis was needed in 7 cases (20%). CONCLUSIONS TIPS is safe and effective. While its benefit for patients with portal hypertension is clear, the role of TIPS in treatment of portal-mesenteric venous thrombosis needs further evaluation. Patient selection, establishing the indication and performing TIPS should be done by a multidisciplinary dedicated team.

[1]  E. Shabtai,et al.  Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality. , 2006, The Israel Medical Association journal : IMAJ.

[2]  W Gerok,et al.  NEW NON-OPERATIVE TREATMENT FOR VARICEAL HAEMORRHAGE , 1989, The Lancet.

[3]  M. Kutner,et al.  Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. , 2006, Gastroenterology.

[4]  Ziv J Haskal,et al.  The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009 , 2010, Hepatology.

[5]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[6]  P. Eliáš,et al.  [Transjugular intrahepatic portosystemic shunt]. , 1993, Cor et vasa.

[7]  R. Uflacker.  Applications of percutaneous mechanical thrombectomy in transjugular intrahepatic portosystemic shunt and portal vein thrombosis. , 2003, Techniques in vascular and interventional radiology.

[8]  A. Rosemurgy,et al.  TIPS Versus Peritoneovenous Shunt in the Treatment of Medically Intractable Ascites: A Prospective Randomized Trial , 2004, Annals of surgery.

[9]  D. Samuels,et al.  Budd-chiari syndrome and acute portal vein thrombosis: management by a transjugular intrahepatic portosystemic shunt (tips) and portal vein interventions via a tips , 2006, Journal of Gastrointestinal Surgery.

[10]  D. Valla,et al.  TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. , 2008, Gastroenterology.

[11]  I. Keussen,et al.  Interventional radiological management of prehepatic obstruction of [corrected] the splanchnic venous system. , 2007, Cardiovascular and interventional radiology.

[12]  G. Bastarrika,et al.  The role of transjugular intrahepatic portosystemic shunt prior to abdominal tumoral surgery in cirrhotic patients with portal hypertension. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  V. Arroyo,et al.  Management of cirrhosis and ascites. , 2004, The New England journal of medicine.

[14]  Franz Hackl,et al.  Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE‐covered stentgrafts versus bare stents , 2003, Hepatology.

[15]  M Peck-Radosavljevic,et al.  Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt , 2003, Gut.

[16]  Klaus Haag,et al.  Hepatic arterial buffer response in patients with advanced cirrhosis , 2002, Hepatology.

[17]  T. Boyer,et al.  Transjugular intrahepatic portosystemic shunt: current status. , 2003, Gastroenterology.

[18]  H. Bismuth,et al.  Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. , 2001, Journal of the American College of Surgeons.

[19]  J. Hoofnagle,et al.  The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. , 1995, Hepatology.

[20]  J. García‐Pagán,et al.  TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial , 2002, Hepatology.

[21]  M. Rössle.  How much reduction in portal pressure is necessary to prevent variceal rebleeding? a longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts , 2001 .

[22]  Ziv J Haskal,et al.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension , 2005, Hepatology.

[23]  D. Rockey,et al.  Gastroesophageal variceal hemorrhage. , 2001, The New England journal of medicine.

[24]  D. Valla,et al.  Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow‐up study , 2010, Hepatology.

[25]  Alessio Farcomeni,et al.  Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts , 2008, The American Journal of Gastroenterology.